Replies to post #126122 on Titan Medical Inc (TMDIF)

[BigT82]

Here you go BigK:

For those who are not familiar with BO calculations here schematicaly summarized.
1. Prospects of a Premarket Company are estimated regarding potential market share gain
2. Profitability is calculated on earnings before tax and depreciation
3. BO prize is calculated based on 1 + 2 and discounted (X%) and potentially leveraged due to strategic reasons.

Due to figures presented at the SRS by Goldman Sachs Global Investment research the Us Medical Robotics Market has been In 2019 and will grow to in 2025/2030 in Billion §:
# Soft Tissue Robotic Revenue 3,5/8,1/12,2
# Hard Tissue Robotic Revenue 0,3/ 1,1/1,7
# Flexibel Endoluminal Robotic Revenue 0,0/0,9/2,8

If Martha aims for minimum 25% marketshare cumulative revenue soft tissue for the years 2022 to 2028 would be about 15 Billion.
One can estimate that the rest of the world may contribute half the amount in total so we talk about 22 to 25 Billion for soft Tissue.
Lets assume profitability is minimum 30 % we came up with earnings 6 to 7 Billions. In this case I would guess strategic reasons equalize discounting. MDT payed 1,5 Billion for a 0,3 billion market. J&J payed 3,6 Billion for a non existing market.
I wonder what MDT will pay for the biggest market.
Thanks
Facetrain